- Clinical application of 3D-Cancer map based on MRI-US fusion biopsy
- Transperineal prostate biopsy: When and whom
- Prostate cancer: Prognostic and therapeutic tissue markers
- Where are we at in screening with PSA?
- Use of biomarkers in selecting patients for active surveillance and focal ablation
- Germline mutations in metastatic prostate cancer: Influence on treatment selection
- Integrative oncology in prostate cancer
- Dietary modifications after prostate cancer diagnosis
- New approaches in non-surgical treatment of localized prostate cancer: HIFU, CRYO
- Lu-177 in the treatment algorithm: How does it stack up?
- Alpharidin in metastatic prostate cancer
- Primary radiotherapy in metastatic prostate cancer
- Therapeutic shift in hormone sensitive prostate cancer
- Therapeutic options in non-metastatic castration-resistant prostate cancer
- Case discussions -Prostate
- Whats new in urinary cytology in the evaluation of urothelial cancer
- VI-RADS (Vesical imaging-Reporting and data system)
- Optimal and emerging treatments for NMIBC
- Robotic cystectomy and urinary diversion
- Future of surgery 2040
- Bladder cancer and immunotherapy
- Anti-FGFR agents for bladder cancer
- Options for patients not eligible for cystectomy
- Panel discussion: Optimizing management of high risk NMIBC – Case based discussion
- Does maximal TURBT improve outcomes prior to cystectomy or neoadjuvant chemotherapy?
- Pro/Con: Role of surgery in regional lymph node metastatic urothelial cancers
- Case discussions -Bladder (30′)
- New perspectives in the management of upper tract urothelial carcinoma
- Neoadjuvant vs. adjuvant chemotherapy for UTUC
- Rare hereditary renal cell carcinomas: What the radiologist need to know
- Emerging biomarkers and therapeutic targets for renal cell carcinoma
- Radiologic evaluation of sub types in renal masses
- Surveillance for renal cell carcinoma: Is there a better way?
- Interactive panel discussion: Integrating surgery and systemic therapy for locally advanced and metastatic RCC
- Overview of challenges in adjuvant RCC trials
- Case discussions -Kidney
- Serum MicroRNA as a novel tumor marker for testicular germ cell tumor
- Primary RPLND in stage I-IIa testicle tumors
- Pro/Con: Minimally invasive RPLND
- Update on role of surgical salvage/late relapse surgery in advanced GCT
- Whats new in the systemic treatment of testicular cancer
- Introduction to Molecular biology for clinicians
- Basic consepts in immuno-oncology
- Current status of pelvic lymphadenectomy: To do or not to do
- Epigenetic regulation of OCT1 in castration resistant prostate cancer cells
- Urobiome and bladder cancer: a new era for research
- Perineal approach to prostate – Why? When?
- Updated bilateral adrenectomy, use of ICG